
Francesca Buttini

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4536793/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Surface-Modified Nanocarriers for Nose-to-Brain Delivery: From Bioadhesion to Targeting. Pharmaceutics, 2018, 10, 34.	2.0	206
2	Overview on gastroretentive drug delivery systems for improving drug bioavailability. International Journal of Pharmaceutics, 2016, 510, 144-158.	2.6	194
3	Opportunity and challenges of nasal powders: Drug formulation and delivery. European Journal of Pharmaceutical Sciences, 2018, 113, 2-17.	1.9	83
4	Effect of Flow Rate on <i>In Vitro</i> Aerodynamic Performance of NEXThaler [®] in Comparison with Diskus [®] and Turbohaler [®] Dry Powder Inhalers. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2016, 29, 167-178.	0.7	78
5	Particles and powders: Tools of innovation for non-invasive drug administration. Journal of Controlled Release, 2012, 161, 693-702.	4.8	59
6	Pulmonary Spray Dried Powders of Tobramycin Containing Sodium Stearate to Improve Aerosolization Efficiency. Pharmaceutical Research, 2009, 26, 1084-1092.	1.7	56
7	Lecithin/chitosan controlled release nanopreparations of tamoxifen citrate: Loading, enzyme-trigger release and cell uptake. Journal of Controlled Release, 2013, 167, 276-283.	4.8	55
8	Ex vivo permeation of tamoxifen and its 4-OH metabolite through rat intestine from lecithin/chitosan nanoparticles. International Journal of Pharmaceutics, 2015, 491, 99-104.	2.6	49
9	Spray-dried amikacin sulphate powder for inhalation in cystic fibrosis patients: The role of ethanol in particle formation. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 93, 165-172.	2.0	46
10	Surface engineering of Solid Lipid Nanoparticle assemblies by methyl α- d -mannopyranoside for the active targeting to macrophages in anti-tuberculosis inhalation therapy. International Journal of Pharmaceutics, 2017, 528, 440-451.	2.6	46
11	Differences in physical chemistry and dissolution rate of solid particle aerosols from solution pressurised inhalers. International Journal of Pharmaceutics, 2014, 465, 42-51.	2.6	45
12	The application of Quality by Design framework in the pharmaceutical development of dry powder inhalers. European Journal of Pharmaceutical Sciences, 2018, 113, 64-76.	1.9	45
13	Spray dried amikacin powder for inhalation in cystic fibrosis patients: A quality by design approach for product construction. International Journal of Pharmaceutics, 2014, 471, 507-515.	2.6	44
14	Critical Characteristics for Corticosteroid Solution Metered Dose Inhaler Bioequivalence. Molecular Pharmaceutics, 2012, 9, 563-569.	2.3	42
15	Engineered sodium hyaluronate respirable dry powders for pulmonary drug delivery. International Journal of Pharmaceutics, 2017, 517, 286-295.	2.6	41
16	Newly synthesized surfactants for surface mannosylation of respirable SLN assemblies to target macrophages in tuberculosis therapy. Drug Delivery and Translational Research, 2019, 9, 298-310.	3.0	41
17	Solid Lipid Nanoparticle assemblies (SLNas) for an anti-TB inhalation treatmentâ;;A Design of Experiments approach to investigate the influence of pre-freezing conditions on the powder respirability. International Journal of Pharmaceutics, 2016, 511, 669-679.	2.6	39
18	"Pierce and inhale―design in capsule based dry powder inhalers: Effect of capsule piercing and motion on aerodynamic performance of drugs. International Journal of Pharmaceutics, 2015, 487, 197-204.	2.6	38

FRANCESCA BUTTINI

#	Article	IF	CITATIONS
19	Inhalable chitosan microparticles for simultaneous delivery of isoniazid and rifabutin in lung tuberculosis treatment. Drug Development and Industrial Pharmacy, 2019, 45, 1313-1320.	0.9	38
20	Loco-regional administration of nanomedicines for the treatment of lung cancer. Drug Delivery, 2016, 23, 2881-2896.	2.5	36
21	Effect of polymers for aerolization properties of mannitol-based microcomposites containing meloxicam. European Polymer Journal, 2013, 49, 2518-2527.	2.6	35
22	Inhalable Fucoidan Microparticles Combining Two Antitubercular Drugs with Potential Application in Pulmonary Tuberculosis Therapy. Polymers, 2018, 10, 636.	2.0	34
23	100 Years of Drug Delivery to the Lungs. Handbook of Experimental Pharmacology, 2019, 260, 143-159.	0.9	34
24	Back to basics: The development of a simple, homogenous, twoâ€component dryâ€powder inhaler formulation for the delivery of budesonide using miscible vinyl polymers. Journal of Pharmaceutical Sciences, 2008, 97, 1257-1267.	1.6	30
25	Pure insulin highly respirable powders for inhalation. European Journal of Pharmaceutical Sciences, 2014, 51, 110-117.	1.9	30
26	Dry powders for the inhalation of ciprofloxacin or levofloxacin combined with a mucolytic agent for cystic fibrosis patients. Drug Development and Industrial Pharmacy, 2017, 43, 1378-1389.	0.9	28
27	Dose administration maneuvers and patient care in tobramycin dry powder inhalation therapy. International Journal of Pharmaceutics, 2018, 548, 182-191.	2.6	27
28	Towards the bioequivalence of pressurised metered dose inhalers 1: Design and characterisation of aerodynamically equivalent beclomethasone dipropionate inhalers with and without glycerol as a non-volatile excipient. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 86, 31-37.	2.0	26
29	Sodium Hyaluronate Nanocomposite Respirable Microparticles to Tackle Antibiotic Resistance with Potential Application in Treatment of Mycobacterial Pulmonary Infections. Pharmaceutics, 2019, 11, 203.	2.0	26
30	Dual antibiotherapy of tuberculosis mediated by inhalable locust bean gum microparticles. International Journal of Pharmaceutics, 2017, 529, 433-441.	2.6	25
31	Multilayer PVA adsorption onto hydrophobic drug substrates to engineer drug-rich microparticles. European Journal of Pharmaceutical Sciences, 2008, 33, 20-28.	1.9	23
32	Multiple dosing of simvastatin inhibits airway mucus production of epithelial cells: Implications in the treatment of chronic obstructive airway pathologies. European Journal of Pharmaceutics and Biopharmaceutics, 2013, 84, 566-572.	2.0	23
33	Floating modular drug delivery systems with buoyancy independent of release mechanisms to sustain amoxicillin and clarithromycin intra-gastric concentrations. Drug Development and Industrial Pharmacy, 2016, 42, 332-339.	0.9	23
34	Nebulized coenzyme Q 10 nanosuspensions: A versatile approach for pulmonary antioxidant therapy. European Journal of Pharmaceutical Sciences, 2018, 113, 159-170.	1.9	23
35	Formulating powder–device combinations for salmeterol xinafoate dry powder inhalers. International Journal of Pharmaceutics, 2015, 490, 360-367.	2.6	21
36	Anti-inflammatory flurbiprofen nasal powders for nose-to-brain delivery in Alzheimer's disease. Journal of Drug Targeting, 2019, 27, 984-994.	2.1	21

FRANCESCA BUTTINI

#	Article	IF	CITATIONS
37	Excipient-free pulmonary insulin dry powder: Pharmacokinetic and pharmacodynamics profiles in rats. Journal of Controlled Release, 2020, 323, 412-420.	4.8	21
38	Layered lipid microcapsules for mesalazine delayed-release in children. International Journal of Pharmaceutics, 2011, 421, 293-300.	2.6	20
39	Combinations of colistin solutions and nebulisers for lung infection management in cystic fibrosis patients. International Journal of Pharmaceutics, 2016, 502, 242-248.	2.6	19
40	Aerosolization Performance of Jet Nebulizers and Biopharmaceutical Aspects. Pharmaceutics, 2019, 11, 406.	2.0	18
41	The Impact of Lipid Corona on Rifampicin Intramacrophagic Transport Using Inhaled Solid Lipid Nanoparticles Surface-Decorated with a Mannosylated Surfactant. Pharmaceutics, 2019, 11, 508.	2.0	18
42	Inhalable Spray-Dried Chondroitin Sulphate Microparticles: Effect of Different Solvents on Particle Properties and Drug Activity. Polymers, 2020, 12, 425.	2.0	17
43	Spray-dried fucoidan microparticles for pulmonary delivery of antitubercular drugs. Journal of Microencapsulation, 2018, 35, 392-405.	1.2	15
44	The role of the solid state and physical properties of the carrier in adhesive mixtures for lung delivery. Expert Opinion on Drug Delivery, 2018, 15, 665-674.	2.4	14
45	A respirable HPV-L2 dry-powder vaccine with GLA as amphiphilic lubricant and immune-adjuvant. Journal of Controlled Release, 2021, 340, 209-220.	4.8	14
46	Understanding the Importance of Capsules in Dry Powder Inhalers. Pharmaceutics, 2021, 13, 1936.	2.0	14
47	High shear mixing of lactose and salmeterol xinafoate dry powder blends: Biopharmaceutic and aerodynamic performances. Journal of Drug Delivery Science and Technology, 2015, 30, 443-449.	1.4	13
48	Micro/nanosystems and biomaterials for controlled delivery of antimicrobial and anti-biofilm agents. Expert Opinion on Therapeutic Patents, 2020, 30, 983-1000.	2.4	13
49	Consequences of not-shaking and shake-fire delays on the emitted dose of some commercial solution and suspension pressurized metered dose inhalers. Expert Opinion on Drug Delivery, 2020, 17, 1025-1039.	2.4	13
50	Inhalable Microparticles Embedding Calcium Phosphate Nanoparticles for Heart Targeting: The Formulation Experimental Design. Pharmaceutics, 2021, 13, 1825.	2.0	13
51	Esomeprazole immediate release tablets: Gastric mucosa ex vivo permeation, absorption and antisecretory activity in conscious rats. Journal of Controlled Release, 2016, 239, 203-210.	4.8	12
52	Methacholine dry powder inhaler as a new tool for bronchial challenge test. International Journal of Pharmaceutics, 2008, 352, 165-171.	2.6	11
53	Multivariate Analysis of Effects of Asthmatic Patient Respiratory Profiles on the In Vitro Performance of a Reservoir Multidose and a Capsule-Based Dry Powder Inhaler. Pharmaceutical Research, 2016, 33, 701-715.	1.7	11
54	In Vitro Evaluation of Curcumin- and Quercetin-Loaded Nanoemulsions for Intranasal Administration: Effect of Surface Charge and Viscosity. Pharmaceutics, 2022, 14, 194.	2.0	11

FRANCESCA BUTTINI

1

#	Article	IF	CITATIONS
55	Multi-kinetics and site-specific release of gabapentin and flurbiprofen from oral fixed-dose combination: in vitro release and in vivo food effect. Journal of Controlled Release, 2017, 262, 296-304.	4.8	10
56	Lipid-core nanocapsules are an alternative to the pulmonary delivery and to increase the stability of statins. Journal of Microencapsulation, 2019, 36, 317-326.	1.2	10
57	Carrageenan from red algae: an application in the development of inhalable tuberculosis therapy targeting the macrophages. Drug Delivery and Translational Research, 2020, 10, 1675-1687.	3.0	10
58	Curcumin and Quercetin-Loaded Lipid Nanocarriers: Development of Omega-3 Mucoadhesive Nanoemulsions for Intranasal Administration. Nanomaterials, 2022, 12, 1073.	1.9	10
59	Accessorized DPI: a Shortcut towards Flexibility and Patient Adaptability in Dry Powder Inhalation. Pharmaceutical Research, 2016, 33, 3012-3020.	1.7	9
60	Resistant Tuberculosis: the Latest Advancements of Second-line Antibiotic Inhalation Products. Current Pharmaceutical Design, 2021, 27, 1436-1452.	0.9	9
61	Mannitol Polymorphs as Carrier in DPIs Formulations: Isolation Characterization and Performance. Pharmaceutics, 2021, 13, 1113.	2.0	9
62	Dry powder inhaler of colistimethate sodium for lung infections in cystic fibrosis: optimization of powder construction. Drug Development and Industrial Pharmacy, 2019, 45, 1664-1673.	0.9	8
63	Hybrid Nanoparticles as a Novel Tool for Regulating Psychosine-Induced Neuroinflammation and Demyelination In Vitro and Ex vivo. Neurotherapeutics, 2021, 18, 2608-2622.	2.1	7
64	Evaluation of the Physico-mechanical Properties and Electrostatic Charging Behavior of Different Capsule Types for Inhalation Under Distinct Environmental Conditions. AAPS PharmSciTech, 2020, 21, 128.	1.5	7
65	RespiCellTM: An Innovative Dissolution Apparatus for Inhaled Products. Pharmaceutics, 2021, 13, 1541.	2.0	6
66	Complex product composition generates risks for generic substitution also with dosage forms for intravenous administration. International Journal of Pharmaceutics, 2013, 451, 50-56.	2.6	4
67	Design and Characterization of Maltoheptaose-b-Polystyrene Nanoparticles, as a Potential New Nanocarrier for Oral Delivery of Tamoxifen. Molecules, 2021, 26, 6507.	1.7	4
68	Recent Patents on Nasal Vaccines Containing Nanoadjuvants. Recent Advances in Drug Delivery and Formulation, 2022, 16, 103-121.	0.3	3
69	Pulmonary delivery of a p38 α/β MAP kinase inhibitor: bioanalytical method validation and biodistribution in rat plasma and respiratory tissues. European Journal of Pharmaceutical Sciences, 2020, 149, 105341.	1.9	2
70	Nanostructures for Overcoming the Pulmonary Barrier: Drug Delivery Strategies. RSC Drug Discovery Series, 2012, , 273-299.	0.2	2
71	Quality of Inhalation Products: Specifications. , 2013, , 169-190.		1

Biological In Vitro Models for Absorption by Non-Oral Routes. , 2013, , .

5

#	Article	IF	CITATIONS
73	Inhalable cyclosporine powder for immunosuppressive treatment. , 2021, , .		Ο